Physician profile
Ryan J Brown
NPI 1972890952
$681.58
in general payments reported to CMS, 2019-2025
12 companies · $44.67 in 2025
The $44.67 reported for 2025 was less than what a typical Anesthesiology provider received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.48 · 2020: $277 · 2021: $90.97 · 2022: $45.38 · 2023: $141 · 2024: $39.66 · 2025: $44.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $225.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $153.82 | 2019-2024 | Exparel |
| Abbvie INC. | $108.58 | 2020 | |
| Chiesi USA, INC. | $82.83 | 2020-2021 | |
| Heron Therapeutics, INC. | $61.00 | 2023 | Aponvie |
| Merck Sharp & Dohme LLC | $54.75 | 2019-2024 | Bridion |
| La Jolla Pharmaceutical Company | $51.29 | 2022-2023 | Giapreza |
| Revance Therapeutics, INC. | $44.67 | 2025 | Daxxify |
| Acacia Pharma INC | $39.20 | 2021 | |
| Eagle Pharmaceuticals, INC. | $35.82 | 2023 | |
| Masimo Corporation | $21.56 | 2023 | Sedline |
| Mindray Ds USA, INC. | $16.67 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $11.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.